Press Releases

The treatment phase of the clinical trial phase I for MGN1703 in the U.S. was finished according to plan. In terms of safety and tolerability no significant clinical events were observed to date. The study will be completed on schedule until...

The first subject has been enrolled to the clinical trial phase I for MGN1703 in the U.S. It is planned to recruit 14 healthy volunteers and to finalize the study before the end of this year. MOLOGEN expects that first results will become available...

• Three different compounds in clinical development process
• Progress leads to slight increase in research expenses
• Financial environment remains solid

• Randomized, controlled trial to evaluate efficacy
• MGN1703 expanded by a further indication with high unmet medical need

The U.S. Food and Drug Administration (FDA) as well as the responsible Institutional Review Board have approved the phase I clinical trial with MGN1703. The placebo-controlled, double-blind study determines the cardiac safety of MGN1703 in healthy...

• Phase I trial to evaluate safety and tolerability
• Trial is under supervision of Charité - Universitaetsmedizin Berlin

• Application of MGN1703 expanded by a further indication with high unmet medical need
• Randomized, controlled trial to evaluate efficacy
• Study will be conducted in collaboration with the German ABC group